PD01-1: Safety of darolutamide (DARO) for non-metastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial

PD01-2: Pelvic lymph node dissection using indocyanine green fluorescence lymphangiography in robotic assisted radical prostatectomy for non-lymph node or distant metastasis prostate cancer patients.

PD01-3: Association of human polyomavirus, JC and BK virus, infection with prostate cancer in Taiwan

PD01-4: Delayed foley catheter removal after robotic assisted laparoscopic prostatectomy

PD01-5: MicroRNA-107 enhances radiosensitivity by suppressing granulin in PC-3 prostate cancer cells

PD01-6: Development of a nomogram with combined prostate health index and multiparametric magnetic resonance imaging for predicting extracapsular extension in radical prostatectomy specimens